Envoy Medical, Inc.
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
COCH$7.10-0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit Number | Description | Schedule/ Form | File No. | Exhibit | Filing Date |
| 2.1 (+) | Business Combination Agreement, dated as of April 17, 2023, by and among Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc. and Envoy Medical Corporation. | 8-K | 001-40133 | 2.1 | April 18, 2023 |
| 2.2 | Amendment No. 1 to the Business Combination Agreement, dated May 12, 2023, by and among Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc. and Envoy Medical Corporation. | S-4 | 333-271920 | 2.2 | May 15, 2023 |
| 2.3 | Amendment No. 2 to the Business Combination Agreement, dated August 31, 2023, by and among Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc. and Envoy Medical Corporation. | S-4/A | 333-271920 | 2.3 | September 1, 2023 |
| 3.1 | Second Amended and Restated Certificate of Incorporation of the Company. | 8-K | 001-40133 | 3.1 | October 5, 2023 |
| 3.2 | Amended and Restated Bylaws of the Company. | 8-K | 001-40133 | 3.2 | October 5, 2023 |
| 3.3 | Certificate of Designation of Series A Preferred Stock of the Company. | 8-K | 001-40133 | 3.3 | October 5, 2023 |
| 4.1 | Warrant Agreement, dated March 1, 2021, between Anzu Special Acquisition Corp I and Equiniti Trust Company, LLC (formerly known as American Stock Transfer & Trust Company, LLC), as Warrant Agent. | 8-K | 001-40133 | 10.1 | March 4, 2021 |
| 4.2 | Form of Shortfall Warrant. | S-1/A | 333-276590 | 4.2 | February 15, 2024 |
| 4.3 | Description of Securities. | 10-K | 001-40133 | 4.3 | April 1, 2024 |
| 4.4 | Form of Private Warrant. | 10-K | 001-0133 | 4.4 | March 31, 2025 |
| 10.1 | At The Market Offering Agreement, dated January 17, 2025, between Envoy Medical, Inc and Roth Capital Partners, LLC. | 8-K | 001-40133 | 10.1 | January 21, 2025 |
| 10.2 (*) | Promissory Note, dated March 6, 2025, between Envoy Medical, Inc. and GAT Funding, LLC. | ||||
| 31.1 (*) | Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). | ||||
| 31.2 (*) | Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). | ||||
| 32.1 (**) | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2 (**) | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101 | The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Unaudited Condensed Balance Sheets; (ii) Unaudited Condensed Statements of Operations; (iii) Unaudited Condensed Statements of Changes in Stockholders’ Equity; (iv) Unaudited Condensed Statement of Cash Flows; and (v) Notes to Unaudited Condensed Financial Statements. | ||||
| 104(#) | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | ||||
| (*) | Filed herewith. |
| (**) | Furnished herewith. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.